In 279 adults with episodic migraine, 12 weeks of daily app-based self-administered biofeedback reduced monthly migraine days by 0.9 vs 0.0 with waitlist control at weeks 9–12 (difference 0.9 days; P=0.002). Nine mild device-related adverse events.
RCTn = 279
Poole et al. App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial